8:30am | Opening Registration & Morning Coffee

Emerging Strategies to Target a Broad Range of RAS Mutations

9:00 am T-Cell Receptor Targeting of Multiple RAS Mutant Forms in Broad Patient Populations


  • Characterization of RAS T-cell receptor (TCR) targets
  • TCR discovery and characterization for multiple RAS mutations
  • Challenge and propose of TCR-modified cell therapies targeting RAS mutations

9:25 am 2nd Generation Antigen Presenting Cells for Multiple KRAS Mutations


  • SQZ APC mechanism overcomes challenges of previous cancer vaccines with CD8 T-cell activation and can be enhanced with mRNA cargo combinations
  • SQZ APC clinical program overview: Safety and manufacturability of SQZ’s APC candidate in solid tumors
  • Preclinical data for SQZ’s enhanced APC platform in targeting KRAS G12D and G12V mutation

9:50 am Chemotype Evolution Platform for Discovering Covalent Inhibitors of KRAS G12C & Beyond

  • Jack Sadowsky Principal Investigator of Discovery Chemistry, Carmot Therapeutics


  • We will present the development of Chemotype Evolution for rapid, highthroughput identification and advancement of covalent inhibitors
  • Challenges faced and overcome in the construction and screening of covalent warhead-fragment libraries will be described
  • We will describe the deployment of our approach to identify potent covalent inhibitors of KRAS G12C

10:15 am Anima’s Pan-KRAS mRNA Translation Modulators in mKRAS Driven Tumors

  • Kevin Pong Vice President, Business Development , Anima Biotech


  • mRNA Lightning for the discovery of selective small molecules mRNA drugs and platform applications in oncology
  • KRAS mRNA translation as a driver for tumorigenesis
  • Mutations independent modulation of mRNA Biology in mKRAS driven tumors


10:40 am Live Panel Q&A – Ask the Speakers Your Burning Questions

  • Hugh Slater Chief Scientific Officer, Anocca
  • Armon Sharei CEO & Founder, SQZ Biotechnologies
  • Jack Sadowsky Principal Investigator of Discovery Chemistry, Carmot Therapeutics
  • Kevin Pong Vice President, Business Development , Anima Biotech

11.00am | Structured Networking & Refreshment Break


As the RAS community is reunited, this valuable session will ensure you can reconnect with your peers in the room to make new and lasting connections. Running concurrently as an in-person and digital session, all attendees will have the opportunity to meet and network with their academic and industry colleagues

Novel Biologics & Degradation Mediated Strategies Against RAS Mutant Cancers

12:00 pm PROTAC Mediated Degradation of KRAS


  • KRAS PROTACs that employ novel ubiquitin ligase and degrade different KRAS isoforms will be the subject of this talk
  • Current methods for PROTAC discovery are not optimal. Use of PROTAC mediated in-vitro ubiquitination to expedite discovery of novel PROTACs
  • Me too ligase, VHL and Cereblon do not offer specificity for certain targets. Relationship between in vitro and in vivo ubiquitination and PROTAC mediated degradation will be discussed

12:25 pm Targeting KRAS with Mutant Selective Monoclonal Antibodies


  • Generation of mutant selective monoclonal antibodies
  • Functional characterization of antibodies
  • Anti-tumor activity in a xenograft tumor model

12:50 pm Live Panel Q&A – Ask the Speakers Your Burning Questions

1:00pm | Lunch & Poster Session – Present, Learn & Collaborate


As the landscape of innovative discovery efforts to target RAS G12C &beyond expands, it is more important than ever to collaborate and learn with your peers as we continue to advance RAS targeted therapies through discovery. Join our dedicated session to share your latest data and have a first look about what your peers are working on!

2:00 pm Increasing the Throughput of Ligandable Cysteine Hotspots Profiling by Mass Spectrometry to Guide RAS Pathway Drug Discovery


  • Hotspots are accessible, reactive and ligandable residues that can serve as covalent drug targets
  • Systematic cataloging of the hotspots present in a cellular proteome is instrumental for advancements in drug discovery
  • We implemented sample hyperplexing into an activity-based proteome profiling (ABPP) workflow to increase the depth and throughput of ligandable cysteine hotspots identification by mass spectrometry

2:25 pm Developing Genomic Medicines for KRAS-Driven Cancers


  • Strategies for using gene regulation in treating KRAS-driven cancers
  • Machine learning and 3D modeling of genomic neighborhoods relevant to KRAS expression
  • Design and validation of locus regulators for treatment of KRAS-driven NSCLC

2:50 pm Multi-Omics Data Integration Reveals Emerging Targets for RAS Mutant Cancers

  • Greg Jones Principle Scientist, Team Leader, Pfizer


  • Targeting KRAS has proven clinical value for G12C mutant tumors – can this be expanded by a new wave of target ID, with distinct activity in intrinsic or acquired resistant models to G12C inhibition?
  • Utilizing a combination of KRASG12Ci Resistant cell line models, and in vivo CRISPR drop out screens, reveals new targets required for the tumor maintenance of RAS mutant cancers
  • Rationale for predicting biomarker response to emerging targets beyond RAS mutational status

3:15 pm Live Panel Q&A – Ask the Speakers Your Burning Questions

3:30pm | Chair’s Closing Remarks & End of 3rd RAS/MAPK Pathway Targeted Drug Discovery Summit